#USA #South San Francisco #Universal Vaccine #Centivax #Emery Pharma

Centivax and Emery Pharma: A Strategic Collaboration for Universal Vaccine Development

In a significant move to expedite the readiness of a universal vaccine, Centivax, a biotechnology firm recognized for creating broad-spectrum vaccines, has forged an alliance with Emery Pharma, a reputable contract research organization. This partnership aims to combine both parties' strengths, focusing on developing an IND-enabling GLP compliant potency release assay for their pan-influenza vaccine candidate, Centi-Flu.

Centivax has dedicated itself to addressing the challenges posed by rapidly evolving pathogens, which requires innovative approaches to vaccine development. With the COVID-19 pandemic highlighting the urgency for effective vaccines, Centivax's mission becomes even more critical. Their first asset, the Centi-Flu vaccine, represents a breakthrough approach to flu vaccinations, promising to deliver comprehensive immunity against various influenza strains.

As part of this partnership, Emery Pharma's vast expertise in GLP and CGMP compliant analytical testing will be harnessed to create a robust mass-spectrometry based potency assay. This assay will serve as the definitive release mechanism for validating the vaccine batches intended not only for clinical trials but also for post-approval commercial use. Emery Pharma's advanced methodologies ensure that every manufactured batch of Centi-Flu maintains uniform potency and quality, an essential aspect for both clinical efficacy and public trust.

Jacob Glanville, CEO of Centivax, emphasized the importance of this collaboration, stating, "Having a trusted partner in Emery Pharma is vital for the rigorous in vitro development of our batch release potency assay. It's important not only for our initial clinical trial phases but also for expediting our entire vaccine development pipeline. With Emery's expertise, we aim to ensure that we deliver a consistently high-quality universal vaccine product, capable of generating long-lasting immunity against flu strains."

Emery Pharma's CEO, Dr. Ron Najafi, also expressed enthusiasm about their role in this collaboration. He noted, "Supporting Centivax in developing these groundbreaking vaccines aligns with our commitment to providing critical testing necessary for validating efficacy early in the development process. By streamlining the pathway from research to clinical trials, we can bolster the scientific foundation on which these vaccines stand."

This partnership represents more than just a collaborative effort; it signifies a step forward in combating global infectious diseases. Both companies aim to revolutionize vaccine technologies and respond to the escalating health challenges posed by various pathogens.

About Centivax

Centivax envisions a future free of infectious diseases through its innovative vaccine approach. The company is on the verge of launching its universal flu vaccine into clinical trials, a process enabled by extensive funding from prestigious entities such as the Bill and Melinda Gates Foundation, NIH, and various military branches. Their technological platform is not only limited to flu vaccines but extends to other therapeutic areas including cancer.

About Emery Pharma

Emery Pharma stands at the forefront of contract research organizations, delivering unparalleled services that include microbiology, bioanalysis, and advanced analytical chemistry. Their committed team of scientists works closely with pharmaceutical and biotech companies to facilitate the development of vital therapeutics.

In summary, the collaboration between Centivax and Emery Pharma exemplifies the synergy required in modern vaccine development, underscoring the importance of reducing timeframes from research to the clinic while ensuring thorough scientific validation. As the world braces itself against future threats from infectious diseases, the efficacy of this partnership will be pivotal in safeguarding public health and advancing biomedical science.